应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01093 石药集团
耶稣受难节休市 03-28 16:08:03
6.150
-0.120
-1.91%
最高
6.300
最低
6.140
成交量
3,294万
今开
6.270
昨收
6.270
日振幅
2.55%
总市值
732.05亿
流通市值
732.05亿
总股本
119.03亿
成交额
2.04亿
换手率
0.28%
流通股本
119.03亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
石药集团03月27日遭主力抛售2638万元 环比增加614.91%
自选股智能写手 · 03-27 16:16
石药集团03月27日遭主力抛售2638万元 环比增加614.91%
减肥药市场激战正酣,石药集团、众生药业竞速GLP-1药物研发
观察者网 · 03-27 10:59
减肥药市场激战正酣,石药集团、众生药业竞速GLP-1药物研发
石药集团“司美格鲁肽”获批减重临床
华尔街见闻 · 03-26
石药集团“司美格鲁肽”获批减重临床
《大行报告》汇丰研究降石药(01093.HK)目标价至7元 创新项目步入正轨
阿斯达克财经 · 03-26
《大行报告》汇丰研究降石药(01093.HK)目标价至7元 创新项目步入正轨
南向资金3月25日净卖出石药集团775.40万股 连续3日减持
自选股智能写手 · 03-26
南向资金3月25日净卖出石药集团775.40万股 连续3日减持
国产“减肥神药”竞速:石药集团司美格鲁肽获批临床,众生药业公布双靶点药物数据
澎湃新闻 · 03-26
国产“减肥神药”竞速:石药集团司美格鲁肽获批临床,众生药业公布双靶点药物数据
石药集团(01093):司美格鲁肽注射液用于超重/肥胖适应症获临床试验批准
智通财经 · 03-25
石药集团(01093):司美格鲁肽注射液用于超重/肥胖适应症获临床试验批准
快讯| 石药集团:司美格鲁肽注射液用于超重\/肥胖适应症获临床试验批准。
腾讯自选股 · 03-25
快讯| 石药集团:司美格鲁肽注射液用于超重\/肥胖适应症获临床试验批准。
石药(01093.HK)司美格鲁肽注射液用于肥胖适应症获准内地临床
阿斯达克财经 · 03-25
石药(01093.HK)司美格鲁肽注射液用于肥胖适应症获准内地临床
石药集团03月25日主力资金流出93万元 连续3日减仓
自选股智能写手 · 03-25
石药集团03月25日主力资金流出93万元 连续3日减仓
【券商聚焦】中泰国际调整石药集团(01093)目标价至9港元 指去年业绩略逊预期
金吾资讯 · 03-25
【券商聚焦】中泰国际调整石药集团(01093)目标价至9港元 指去年业绩略逊预期
石药集团(1093.HK):2023年业绩稳健增长,创新药物研发引领未来
格隆汇 · 03-25
石药集团(1093.HK):2023年业绩稳健增长,创新药物研发引领未来
石药集团(01093):达格列净片获药品注册批件
智通财经 · 03-22
石药集团(01093):达格列净片获药品注册批件
石药(01093.HK)血糖控制药获授药品注册批件
阿斯达克财经 · 03-22
石药(01093.HK)血糖控制药获授药品注册批件
石药集团:毛利率超70%,净利润近五年首次下滑|年报拆解
地产k线 · 03-22
石药集团:毛利率超70%,净利润近五年首次下滑|年报拆解
石药集团:研发投入48亿元,抗肿瘤、心血管药销售额双下滑|年报拆解
瑞财网 · 03-22
石药集团:研发投入48亿元,抗肿瘤、心血管药销售额双下滑|年报拆解
石药凶猛,但想当“医药一哥”还有难度
健识局 · 03-21
石药凶猛,但想当“医药一哥”还有难度
石药集团受创新药增长放缓影响 建银国际调低目标价至9.1港元
和讯网 · 03-21
石药集团受创新药增长放缓影响 建银国际调低目标价至9.1港元
建银国际降石药目标价至9.1港元 创新药不断增加
财通社 · 03-21
建银国际降石药目标价至9.1港元 创新药不断增加
高盛:予石药集团(01093)“买入”评级 目标价升至9.73港元
智通财经 · 03-21
高盛:予石药集团(01093)“买入”评级 目标价升至9.73港元
加载更多
公司概况
公司名称:
石药集团
所属市场:
SEHK
上市日期:
--
主营业务:
石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门:成药部门、抗生素(中间体及原料药)部门、维生素C(原料药)部门及咖啡因及其他(原料药)部门,分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。
发行价格:
--
{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":6.15,"timestamp":1711613283012,"preClose":6.27,"halted":0,"volume":32939080,"delay":0,"floatShares":11903219732,"shares":11903219732,"eps":0.5336624,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":-0.12,"latestTime":"03-28 16:08:03","open":6.27,"high":6.3,"low":6.14,"amount":204006298,"amplitude":0.025518,"askPrice":6.16,"askSize":18000,"bidPrice":6.15,"bidSize":1784000,"shortable":3,"etf":0,"ttmEps":0.5336418734593261,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":772128000000,"adjPreClose":6.27,"dividendRate":0.044549,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":0.6162043814944491,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK"},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2422959106","title":"石药集团03月27日遭主力抛售2638万元 环比增加614.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422959106","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422959106?lang=zh_cn&edition=full","pubTime":"2024-03-27 16:16","pubTimestamp":1711527361,"startTime":"0","endTime":"0","summary":"03月27日, 石药集团股价跌1.26%,报收6.27元,成交金额4.01亿元,换手率0.53%,振幅2.20%,量比1.29。石药集团今日主力资金净流出2638万元,连续5日净流出,上一交易日主力净流出369万元,今日环比增加614.91%。该股近5个交易日下跌1.56%,主力资金累计净流出8532万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出1.49亿元,其中净流出天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271616218b68e3cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271616218b68e3cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422983051","title":"减肥药市场激战正酣,石药集团、众生药业竞速GLP-1药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2422983051","media":"观察者网","top":-1,"share":"https://www.laohu8.com/m/news/2422983051?lang=zh_cn&edition=full","pubTime":"2024-03-27 10:59","pubTimestamp":1711508383,"startTime":"0","endTime":"0","summary":"这一研究成果不仅为石药集团赢得了市场先机,也进一步证明了GLP-1药物在减重领域的巨大潜力。此外,石药集团还在研发另一款GLP-1药物TG103注射液。这一成果为众生药业在GLP-1药物市场的布局增添了重要筹码。随着全球糖尿病药物市场的不断扩大,GLP-1药物成为了各大药企竞相追逐的热点。随着国内药企不断推进GLP-1药物临床试验,未来市场竞争或将愈发激烈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032711003487ba4ad4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032711003487ba4ad4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422669881","title":"石药集团“司美格鲁肽”获批减重临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2422669881","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2422669881?lang=zh_cn&edition=full","pubTime":"2024-03-26 17:23","pubTimestamp":1711444995,"startTime":"0","endTime":"0","summary":"临床前研究结果显示,该产品与 DNA 重组技术制备的司美格鲁肽注射液具有相似的生物活性和减重效果;在食蟹猴体内具有一致的代谢特征和安全性,无全身主动过敏反应且局部耐受性良好。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/2c9f1634-d278-4e3d-84d0-cddc6976ecd2","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/2c9f1634-d278-4e3d-84d0-cddc6976ecd2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3711337","is_publish_highlight":false,"gpt_icon":0},{"id":"2422682604","title":"《大行报告》汇丰研究降石药(01093.HK)目标价至7元 创新项目步入正轨","url":"https://stock-news.laohu8.com/highlight/detail?id=2422682604","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422682604?lang=zh_cn&edition=full","pubTime":"2024-03-26 10:33","pubTimestamp":1711420380,"startTime":"0","endTime":"0","summary":"汇丰环球研究发表报告指,石药去年收入增长1.7%,但纯利下跌3.6%,差过该行预期。展望今年,预期新药推出将会抵销部分产品价格下跌的影响,其快速提升的平台将会支持未来业务研发及长远增长,不过带量采购可能对其主要产品有潜在负面影响。该行指,石药股价年初至今下跌12%,主要因为市场对带量采购的忧虑影响,现价相当于今年预测市盈率11倍,属合理估值,维持其“持有”评级,目标价由7.25元下调至7元。沽空资料截至 2024-03-25 16:25。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230531121547900_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230531121547900_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1336974/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422838286","title":"南向资金3月25日净卖出石药集团775.40万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2422838286","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422838286?lang=zh_cn&edition=full","pubTime":"2024-03-26 09:31","pubTimestamp":1711416674,"startTime":"0","endTime":"0","summary":"3月25日,南向资金减持石药集团775.40万股连续3日减持。截止当日收盘,港股通共持有石药集团151949.10万股,占流通股12.75%。港股通减持金额前五个股分别为中国海洋石油、汇丰控股、泡泡玛特、吉利汽车、中芯国际。石药集团近5个交易日下跌3.06%,港股通累计减持2150.97万股;近20个交易日上涨0.79%,港股通累计减持3512.66万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260945568b634076&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260945568b634076&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422795508","title":"国产“减肥神药”竞速:石药集团司美格鲁肽获批临床,众生药业公布双靶点药物数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2422795508","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422795508?lang=zh_cn&edition=full","pubTime":"2024-03-26 07:04","pubTimestamp":1711407840,"startTime":"0","endTime":"0","summary":"国产“减肥神药”迎来新成员2023年8月,石药集团曾公告称,其司美格鲁肽注射液获批临床用于成人二型糖尿病治疗。石药集团并非首个推动司美格鲁肽注射液的国内药企。今年2月,丽珠集团、翰宇药业等多家药企公告称,司美格鲁肽减重适应证获批临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032607045587b4d77d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032607045587b4d77d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422598775","title":"石药集团(01093):司美格鲁肽注射液用于超重/肥胖适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2422598775","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422598775?lang=zh_cn&edition=full","pubTime":"2024-03-25 17:11","pubTimestamp":1711357867,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 发布公告,该集团开发的司美格鲁肽注射液已获中国国家药品监督管理局批准,可在中国开展用于减少热量饮食和增加体力活动的基础上对成人超重或肥胖患者的体重管理适应症的临床试验,也是该产品继成人2型糖尿病患者的血糖控制后,获批临床试验的第二个适应症。司美格鲁肽注射液是目前减重领域的最大单品,且仍在快速增长,市场前景广阔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1091478.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422859343","title":"快讯| 石药集团:司美格鲁肽注射液用于超重\\/肥胖适应症获临床试验批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2422859343","media":"腾讯自选股","top":-1,"share":"https://www.laohu8.com/m/news/2422859343?lang=zh_cn&edition=full","pubTime":"2024-03-25 17:09","pubTimestamp":1711357782,"startTime":"0","endTime":"0","summary":"石药集团:司美格鲁肽注射液用于超重/肥胖适应症获临床试验批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032516575987e7b709&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032516575987e7b709&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422653593","title":"石药(01093.HK)司美格鲁肽注射液用于肥胖适应症获准内地临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2422653593","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422653593?lang=zh_cn&edition=full","pubTime":"2024-03-25 17:08","pubTimestamp":1711357680,"startTime":"0","endTime":"0","summary":"石药(01093.HK) 发表公告指,集团开发的司美格鲁肽注射液已获中国国家药品监督管理局批准,可在中国开展用于减少热量饮食以及增加体力活动的基础上,对成人超重或肥胖患者的体重管理适应症的临床试验,亦是该产品继成人2型糖尿病患者的血糖控制后,获批临床试验的第二个适应症。司美格鲁肽注射液使用的原料完全通过化学合成法制备,采用先进的合成、纯化和表征技术,制备出的原料纯度更高,避免了因生物发酵过程引入的宿主蛋白等免疫原性物质,并保证杂质水平不高于DNA重组技术制备的司美格鲁肽。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-25 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230531121547900_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230531121547900_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1336664/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422562569","title":"石药集团03月25日主力资金流出93万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2422562569","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422562569?lang=zh_cn&edition=full","pubTime":"2024-03-25 16:16","pubTimestamp":1711354588,"startTime":"0","endTime":"0","summary":"03月25日, 石药集团股价跌1.40%,报收6.34元,成交金额2.25亿元,换手率0.30%,振幅4.20%,量比0.65。石药集团今日主力资金净流出93万元,连续3日净流出,上一交易日主力净流出3096万元,今日环比减少97.00%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为28.57%,平均跌幅为1.54%。该股近5个交易日下跌2.91%,主力资金累计净流出4579万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出1.26亿元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032516170387b21e69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032516170387b21e69&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422156522","title":"【券商聚焦】中泰国际调整石药集团(01093)目标价至9港元 指去年业绩略逊预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2422156522","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422156522?lang=zh_cn&edition=full","pubTime":"2024-03-25 15:25","pubTimestamp":1711351509,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际发研报指,石药集团 2023年收入同比增加1.7%至314.5亿元,较该行预测低2.0%,但在医药企业业绩普遍不佳的情况下保持正增长。由于肿瘤药克艾力集采及疫情后维生素降价等原因,毛利率同比微降1.4个百分点,行政费用略微高于预期,导致股东净利润同比下滑3.6%至58.7亿元,较该行预测低4.5%。由于2023年业绩略逊预期,该行将2024-25E收入及股东净利润预测分别下调4.5%、5.6%及2.6%、6.1%。根据调整后DCF模型,目标价调整至9.00港元,维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032515253787b1e889&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032515253787b1e889&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422581504","title":"石药集团(1093.HK):2023年业绩稳健增长,创新药物研发引领未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2422581504","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2422581504?lang=zh_cn&edition=full","pubTime":"2024-03-25 08:17","pubTimestamp":1711325842,"startTime":"0","endTime":"0","summary":"近日,石药集团发布2023全年业绩公告。数据显示,2023年全年石药集团营业收入达到314.5亿元,同比增长1.7%,归母净利润达到58.7亿元。","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/118.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/118.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/711141","is_publish_highlight":false,"gpt_icon":0},{"id":"2421652148","title":"石药集团(01093):达格列净片获药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2421652148","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2421652148?lang=zh_cn&edition=full","pubTime":"2024-03-22 16:32","pubTimestamp":1711096367,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团(01093)发布公告,集团开发的达格列净片(5mg/10mg)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件,并视同通过仿制药质量和疗效一致性评价。达格列净是一种SGLT2抑制剂,可以使多余的葡萄糖通过尿液被排出体外,从而在不增加胰岛素分泌的情况下改善血糖控制。该产品既可以作为单药治疗,也可作联合治疗,与盐酸二甲双胍或者胰岛素联合使用,在饮食和运动基础上改善血糖控制。该产品的获批将进一步丰富集团在代谢疾病的产品线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1090449.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421989688","title":"石药(01093.HK)血糖控制药获授药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2421989688","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2421989688?lang=zh_cn&edition=full","pubTime":"2024-03-22 16:32","pubTimestamp":1711096320,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布,公司开发的达格列净片已获得国家药监局颁发的药品注册批件,并视同通过仿制药质量和疗效一致性评价。达格列净是一种SGLT2抑制剂,可以使多余的葡萄糖通过尿液被排出体外,从而在不增加胰岛素分泌的情况下改善血糖控制。该产品既可以作为单药治疗,也可作联合治疗,与盐酸二甲双胍或者胰岛素联合使用,在饮食和运动基础上改善血糖控制。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-22 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1336078/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2421881561","title":"石药集团:毛利率超70%,净利润近五年首次下滑|年报拆解","url":"https://stock-news.laohu8.com/highlight/detail?id=2421881561","media":"地产k线","top":-1,"share":"https://www.laohu8.com/m/news/2421881561?lang=zh_cn&edition=full","pubTime":"2024-03-22 09:47","pubTimestamp":1711072053,"startTime":"0","endTime":"0","summary":"瑞财经 吴文婷3月20日,石药集团发布截至2023年12月31日止年度之全年业绩。值得注意的是,其净利润近五年首次出现下滑。而毛利率方面,则维持在70%以上。2019年-2023年,石药集团的毛利率分别为71.98%、74.91%、75.84%、71.94%、70.51%。对于2023年的毛利率下降了1.4个百分点至70.5%,石药集团将原因归结于收入结构变化及维生素C产品销售价格下降所致。资料显示,石药集团是一家集研发、生产和销售为一体的创新驱动型制药企业。相关公司:石药集团hk01093","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220948498b532658&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403220948498b532658&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421168881","title":"石药集团:研发投入48亿元,抗肿瘤、心血管药销售额双下滑|年报拆解","url":"https://stock-news.laohu8.com/highlight/detail?id=2421168881","media":"瑞财网","top":-1,"share":"https://www.laohu8.com/m/news/2421168881?lang=zh_cn&edition=full","pubTime":"2024-03-22 09:44","pubTimestamp":1711071860,"startTime":"0","endTime":"0","summary":"瑞财经 吴文婷 3月20日,石药集团发布截至2023年12月31日止年度之全年业绩。根据公告,2023年公司实现收入314.5亿元,同比增长1.7%;股东应占溢利58.73亿元,同比减少3.6%。 石药集团按成药、原料产品、功能食品及其他划分业务。其中,石药集团的成药业务于2023年度录得收入256.37亿元(包括授权费收入3,470万元),同比增加...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OhSjThMUYBCMyluZvVBpuYXXr30kO8On0V0kGSvVlSmi4AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OhSjThMUYBCMyluZvVBpuYXXr30kO8On0V0kGSvVlSmi4AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240322A01WU000","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240322A01WU000","is_publish_highlight":false,"gpt_icon":0},{"id":"2421017134","title":"石药凶猛,但想当“医药一哥”还有难度","url":"https://stock-news.laohu8.com/highlight/detail?id=2421017134","media":"健识局","top":-1,"share":"https://www.laohu8.com/m/news/2421017134?lang=zh_cn&edition=full","pubTime":"2024-03-21 20:24","pubTimestamp":1711023863,"startTime":"0","endTime":"0","summary":"眼下说“医药一哥”易位,为时尚早。石药遭遇业绩增长天花板分板块来看,石药收入构成主要来自成药、原料药、功能食品。2022年,石药通过并购获得了TNK组织型纤溶酶原激活剂“明复乐”,用于急性心肌梗死发病6小时以内患者的治疗。这被业界认为是石药为抵御“恩必普”专利悬崖所做的准备。这也就导致石药的两个优势领域目前后继无人,短期内营收很难恢复高增长。对新技术的押注,或许会成为未来“一哥”宝座的关键。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032120245687a1f43c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032120245687a1f43c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421051230","title":"石药集团受创新药增长放缓影响 建银国际调低目标价至9.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421051230","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2421051230?lang=zh_cn&edition=full","pubTime":"2024-03-21 12:57","pubTimestamp":1710997078,"startTime":"0","endTime":"0","summary":"建银国际近日发布研报,认为石药集团季销售额增长低于预期,原因包括带量采购引发产品降价以及部分产品领域增长放缓。石药集团季销售额达76亿元人民币,同比增长1.9%,但未能达到预测的81亿元人民币。建银国际对石药集团2024至2026年销售预测均值下调3.3%,并预计由于带量采购带来的价格压力持续,销售及营销开支比率上升,导致同期间每股盈利预测下调5.5%。目标价由9.5港元调整至9.1港元,维持跑赢大市评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032113050887a0358b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032113050887a0358b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421823058","title":"建银国际降石药目标价至9.1港元 创新药不断增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2421823058","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2421823058?lang=zh_cn&edition=full","pubTime":"2024-03-21 11:42","pubTimestamp":1710992520,"startTime":"0","endTime":"0","summary":"3月21日讯,建银国际发表研报指,带量采购导致产品价格下降,加上中枢神经系统及肿瘤领域产品增长放缓,令石药集团 季销售额按年增长1.9%至76亿元人民币,低于预测的81亿元人民币。建银国际将石药2024至2026年销售预测平均下调3.3%,指出带量采购带来的价格压力仍然存在,同时由于销售及营销开支比率提高,将期内每股盈利预测相应下调5.5%,目标价亦从9.5港元下调至9.1港元,维持跑赢大市评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321114211879ff165&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240321114211879ff165&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421373200","title":"高盛:予石药集团(01093)“买入”评级 目标价升至9.73港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2421373200","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2421373200?lang=zh_cn&edition=full","pubTime":"2024-03-21 11:06","pubTimestamp":1710990396,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,高盛发布研究报告称,予石药集团(01093)“买入”评级,计及新产品推出计划,将今明两年纯利预测分别上调1.1%及7%,目标价由9.24港元升至9.73港元。上季石药EBIT超出该行预期,同比升13%至17.7亿元人民币。报告指出,石药集团上季销售额同比增长1.9%至76亿元人民币,符合预期。期内,产品“克艾力”(Ke Aili)虽受到药品集采政策的影响,但集团推出伊立替康脂质体注射液(Irinotecan liposome)等新产品有助抵销部分影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1089595.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.0345},{"period":"3month","weight":-0.1529},{"period":"6month","weight":0.0714},{"period":"1year","weight":-0.1506},{"period":"ytd","weight":-0.1529}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门:成药部门、抗生素(中间体及原料药)部门、维生素C(原料药)部门及咖啡因及其他(原料药)部门,分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.007621},{"month":2,"riseRate":0.733333,"avgChangeRate":0.097752},{"month":3,"riseRate":0.466667,"avgChangeRate":0.01981},{"month":4,"riseRate":0.586207,"avgChangeRate":0.056373},{"month":5,"riseRate":0.586207,"avgChangeRate":0.038691},{"month":6,"riseRate":0.344828,"avgChangeRate":0.00713},{"month":7,"riseRate":0.366667,"avgChangeRate":0.002269},{"month":8,"riseRate":0.433333,"avgChangeRate":0.015994},{"month":9,"riseRate":0.5,"avgChangeRate":-0.005631},{"month":10,"riseRate":0.6,"avgChangeRate":0.0171},{"month":11,"riseRate":0.466667,"avgChangeRate":0.009686},{"month":12,"riseRate":0.5,"avgChangeRate":-0.014286}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}